Selected research
Industry Growth & Trends
Global CD19-targeted CAR-T Cell Therapy Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global CD19-targeted CAR-T Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the CD19-targeted CAR-T Cell Therapy market include Bristol-Myers Squibb (Breyanzi), Gilead (Yescarta&Tecartus), Novartis (Kymriah), FOSUNKite (Yescarta), Juventas and Shanghai Yaoming Juno (Carteyva), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global CD19-targeted CAR-T Cell Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The CD19-targeted CAR-T Cell Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CD19-targeted CAR-T Cell Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CD19-targeted CAR-T Cell Therapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global CD19-targeted CAR-T Cell Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
CD19-targeted CAR-T Cell Therapy Market by Company
Bristol-Myers Squibb (Breyanzi)
Gilead (Yescarta&Tecartus)
Novartis (Kymriah)
FOSUNKite (Yescarta)
Juventas
Shanghai Yaoming Juno (Carteyva)
CD19-targeted CAR-T Cell Therapy Segment by Type
Yescarta
Tecartus
Kymriah
Others
CD19-targeted CAR-T Cell Therapy Segment by Application
Lymphoma
Lymphocytic Leukemia
CD19-targeted CAR-T Cell Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD19-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD19-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD19-targeted CAR-T Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of CD19-targeted CAR-T Cell Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Yescarta
- Tecartus
- Kymriah
- Others
Applications
- Lymphoma
- Lymphocytic Leukemia
Companies covered
- Bristol-Myers Squibb (Breyanzi)
- Gilead (Yescarta&Tecartus)
- Novartis (Kymriah)
- FOSUNKite (Yescarta)
- Juventas
- Shanghai Yaoming Juno (Carteyva)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global CD19-targeted CAR-T Cell Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2032)
- 1.4.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2021-2026)
- 1.4.2 Global CD19-targeted CAR-T Cell Therapy Market Size by Region (2027-2032)
- 1.5 Key Regions CD19-targeted CAR-T Cell Therapy Market Size (2021-2032)
- 1.5.1 North America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (2021-2032)
2 CD19-targeted CAR-T Cell Therapy Market by Type
- 2.1 Type Introduction
- 2.1.1 Yescarta
- 2.1.2 Tecartus
- 2.1.3 Kymriah
- 2.1.4 Others
- 2.2 Global CD19-targeted CAR-T Cell Therapy Market Size by Type
- 2.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global CD19-targeted CAR-T Cell Therapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global CD19-targeted CAR-T Cell Therapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global CD19-targeted CAR-T Cell Therapy Market Size by Regions
- 2.3.1 North America CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Type (2021-2026)
3 CD19-targeted CAR-T Cell Therapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Lymphoma
- 3.1.2 Lymphocytic Leukemia
- 3.2 Global CD19-targeted CAR-T Cell Therapy Market Size by Application
- 3.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global CD19-targeted CAR-T Cell Therapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global CD19-targeted CAR-T Cell Therapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global CD19-targeted CAR-T Cell Therapy Market Size by Regions
- 3.3.1 North America CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa CD19-targeted CAR-T Cell Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 CD19-targeted CAR-T Cell Therapy Industry Trends
- 4.2 CD19-targeted CAR-T Cell Therapy Industry Drivers
- 4.3 CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
- 4.4 CD19-targeted CAR-T Cell Therapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by CD19-targeted CAR-T Cell Therapy Revenue (2021-2026)
- 5.2 Global CD19-targeted CAR-T Cell Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global CD19-targeted CAR-T Cell Therapy Key Company Headquarters & Area Served
- 5.4 Global CD19-targeted CAR-T Cell Therapy Company, Product Type & Application
- 5.5 Global CD19-targeted CAR-T Cell Therapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global CD19-targeted CAR-T Cell Therapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 CD19-targeted CAR-T Cell Therapy Players Market Share by Revenue in 2025
- 5.6.3 2025 CD19-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bristol-Myers Squibb (Breyanzi)
- 6.1.1 Bristol-Myers Squibb (Breyanzi) Company Information
- 6.1.2 Bristol-Myers Squibb (Breyanzi) Business Overview
- 6.1.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.1.5 Bristol-Myers Squibb (Breyanzi) Recent Developments
- 6.2 Gilead (Yescarta&Tecartus)
- 6.2.1 Gilead (Yescarta&Tecartus) Company Information
- 6.2.2 Gilead (Yescarta&Tecartus) Business Overview
- 6.2.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.2.5 Gilead (Yescarta&Tecartus) Recent Developments
- 6.3 Novartis (Kymriah)
- 6.3.1 Novartis (Kymriah) Company Information
- 6.3.2 Novartis (Kymriah) Business Overview
- 6.3.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.3.5 Novartis (Kymriah) Recent Developments
- 6.4 FOSUNKite (Yescarta)
- 6.4.1 FOSUNKite (Yescarta) Company Information
- 6.4.2 FOSUNKite (Yescarta) Business Overview
- 6.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.4.5 FOSUNKite (Yescarta) Recent Developments
- 6.5 Juventas
- 6.5.1 Juventas Company Information
- 6.5.2 Juventas Business Overview
- 6.5.3 Juventas CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.5.5 Juventas Recent Developments
- 6.6 Shanghai Yaoming Juno (Carteyva)
- 6.6.1 Shanghai Yaoming Juno (Carteyva) Company Information
- 6.6.2 Shanghai Yaoming Juno (Carteyva) Business Overview
- 6.6.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio
- 6.6.5 Shanghai Yaoming Juno (Carteyva) Recent Developments
7 North America
- 7.1 North America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)
- 7.3 North America CD19-targeted CAR-T Cell Therapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)
- 8.3 Europe CD19-targeted CAR-T Cell Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)
- 10.3 South America CD19-targeted CAR-T Cell Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst